CORDIS
EU research results

CORDIS

English EN

Amyloid imaging to Prevent Alzheimer’s Disease – Sofia ref.: 115952

Project information

Grant agreement ID: 115952

Status

Ongoing project

  • Start date

    1 October 2016

  • End date

    30 September 2021

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 27 329 288

  • EU contribution

    € 11 999 886

Coordinated by:

STICHTING VUMC

Netherlands

Objective

Beta-amyloid (β-amyloid) deposition is considered to be a necessary - but not sufficient - step on the path towards Alzheimer’s disease (AD). Depiction of brain β-amyloid in vivo can support an early diagnosis, and even provide an opportunity for consider secondary prevention of AD. Currently, however, the value of β-amyloid PET remains elusive, reason why this procedure is typically not reimbursed.

Understanding the value of imaging of β-amyloid using positron emission tomography (PET) provides a unique opportunity to achieve 3 major goals: 1) improve the diagnostic workup of patients suspected of AD and their management; 2) stratify risk for AD and select homogenous groups for intervention; and 3) quantify treatment effects more accurately.

AMYPAD will address the above objectives by studying the onset, dynamics, and clinical relevance of brain β-amyloid
in the spectrum from normal aging to preclinical and prodromal AD. We will use β-amyloid-PET in an unprecedented large number of subjects (n=4000) from population studies, as well as memory clinics cohorts, with repeat imaging in up to 2000. In close collaboration with EPAD (www.ep-ad.org), the cohorts will be followed with to determine (surrogate) outcomes of cognitive decline and neurodegeneration.

Lead from VU-VUmc, the Consortium brings together a word-class team of highly synergistic partners from across Europe constituting a highly experienced and efficient β-amyloid imaging network including the most active European PET sites, to ensure effective tracer delivery, access to patients and expertise to technical knowledge and disease modelling.

AMYPAD will establish the true value of β-amyloid PET across the severity range of AD. Patients and clinicians will benefit from better and cost-effective diagnostic procedures and management, while academics and industry will benefit from better disease understanding, clear reimbursement strategy and more rationale and efficient clinical trial design.

Coordinator

STICHTING VUMC

Address

De Boelelaan 1117
1081 Hv Amsterdam

Netherlands

Activity type

Research Organisations

EU Contribution

€ 5 408 000

Participants (14)

THE UNIVERSITY OF EDINBURGH

United Kingdom

EU Contribution

€ 775 500

FUNDACIO BARCELONABETA BRAIN RESEARCH CENTER

Spain

EU Contribution

€ 1 089 000

UNIVERSITE DE GENEVE

Switzerland

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 650 250

IXICO TECHNOLOGIES LIMITED

United Kingdom

EU Contribution

€ 1 001 136

CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE

France

EU Contribution

€ 558 000

UNIVERSITY COLLEGE LONDON

United Kingdom

EU Contribution

€ 934 500

ALZHEIMER EUROPE

Luxembourg

EU Contribution

€ 200 500

SYNAPSE RESEARCH MANAGEMENT PARTNERS SL

Spain

EU Contribution

€ 557 750

KLINIKUM DER UNIVERSITAET ZU KOELN

Germany

EU Contribution

€ 650 250

GE HEALTHCARE LIMITED

United Kingdom

JANSSEN PHARMACEUTICA NV

Belgium

LIFE MOLECULAR IMAGING LTD

United Kingdom

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 175 000

Project information

Grant agreement ID: 115952

Status

Ongoing project

  • Start date

    1 October 2016

  • End date

    30 September 2021

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 27 329 288

  • EU contribution

    € 11 999 886

Coordinated by:

STICHTING VUMC

Netherlands